Page last updated: 2024-09-05

lapatinib and Cancer of Cervix

lapatinib has been researched along with Cancer of Cervix in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X1
Kurzrock, R; Parker, BA; Schwab, R; Yan, M1
Franckena, M; Kraan, J; Sleijfer, S; van Doorn, L; van Meerten, E; Westermann, A; Wiemer, E1
Ahn, SE; Bae, DS; Cho, YJ; Choi, JJ; Choi, YL; Jung, K; Kim, BG; Kim, S; Lee, JW; Oh, DY; Oh, E; Park, WY; Song, JY; Song, S1
Baltazar, F; Barbosa, AM; Cardoso-Carneiro, D; Cury, FP; de Paula, FE; Evangelista, AF; Granja, S; Longatto-Filho, A; Marques, F; Martinho, O; Miranda-Gonçalves, V; Moreira, MA; Reis, RM; Scapulatempo-Neto, C; Silva-Oliveira, R; Zanon, M1
Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ1

Reviews

1 review(s) available for lapatinib and Cancer of Cervix

ArticleYear
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult

2021

Trials

2 trial(s) available for lapatinib and Cancer of Cervix

ArticleYear
Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.
    The oncologist, 2015, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Lapatinib; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Uterine Cervical Neoplasms

2015
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms

2010

Other Studies

3 other study(ies) available for lapatinib and Cancer of Cervix

ArticleYear
HER2 aberrations in cancer: implications for therapy.
    Cancer treatment reviews, 2014, Volume: 40, Issue:6

    Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms

2014
HER2 as a novel therapeutic target for cervical cancer.
    Oncotarget, 2015, Nov-03, Volume: 6, Issue:34

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; HeLa Cells; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2015
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
    Theranostics, 2017, Volume: 7, Issue:3

    Topics: Acrylamides; Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Biomarkers, Tumor; Diagnostic Tests, Routine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucose; Humans; Lapatinib; Quinazolines; Theranostic Nanomedicine; Therapeutic Uses; Uterine Cervical Neoplasms

2017